Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
By G. Konecny, M. Pegram, N. Venkatesan, R. Finn, Guorong Yang, M. Rahmeh, M. Untch, D. Rusnak, G. Spehar, R. Mullin and 5 more. Cancer Research, 2006
953 citations recorded by the source corpus.
Subfields: Genetics, Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/15b6694cbfe162a89679a226d5c2c81b6909e097
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. (2008, background): “In contrast, a dual HER2-EGFR kinase inhibitor, lapatinib, is clinically active in HER2-positive breast cancer yet displays little activity against breast cancer cell lines that overexpress EGFR (4, 31).”
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009, background): “Lapatinib and trastuzumab are also synergistic in preclinical models, suggesting that these agents could be combined in the clini”
- Treatment of HER2-positive breast cancer: current status and future perspectives (2012, background): “Lapatinib reversibly inhibits the intracellular tyrosine kinase activity of both HER2 and EGFR (also known as HER1), suppressing tyrosine autophosphorylation and thereby downstream pathways, such as the MAPK/Erk1/2 and PI3K/Akt pathways”
- Targeting the EGFR signaling pathway in cancer therapy (2012, background): “3 nmol/L, respectively [94], thus preventing auto phosphorylation and subsequent inhibition of downstream signaling.”